Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study
6/2/2014 9:54:24 AM
BASEL, Switzerland, June 2, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that phase 1 study results of its investigational oncology drug, BAL101553, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, U.S.A. The maximum tolerated dose (MTD) was determined and the results indicated first evidence of clinical antitumor activity.
Help employers find you! Check out all the jobs and post your resume.
comments powered by